$145.63
0.190.13%
Last update: 12:54 PM
15 minutes delayed
Comments
Loading...
Neurocrine Biosciences
NBIXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Neurocrine Biosciences (NASDAQ:NBIX) Stock, Analyst Ratings, Price Targets, Forecasts
Neurocrine Biosciences Inc has a consensus price target of $152.96 based on the ratings of 26 analysts. The high is $216 issued by Oppenheimer on May 2, 2024. The low is $100 issued by Piper Sandler on November 1, 2023. The 3 most-recent analyst ratings were released by Morgan Stanley, JP Morgan, and Morgan Stanley on July 12, 2024, July 10, 2024, and June 12, 2024, respectively. With an average price target of $167.67 between Morgan Stanley, JP Morgan, and Morgan Stanley, there's an implied 15.13% upside for Neurocrine Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
JP Morgan
Wedbush
UBS
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for Neurocrine Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/12/2024 | Buy Now | 16.73% | Morgan Stanley | Jeffrey Hung | $160 → $170 | Maintains | Overweight | Get Alert |
| 07/10/2024 | Buy Now | 18.79% | JP Morgan | Anupam Rama | $169 → $173 | Maintains | Overweight | Get Alert |
| 06/12/2024 | Buy Now | 9.87% | Morgan Stanley | Jeffrey Hung | $160 → $160 | Maintains | Overweight | Get Alert |
| 05/29/2024 | Buy Now | 4.37% | Wedbush | Laura Chico | → $152 | Reiterates | Outperform → Outperform | Get Alert |
| 05/28/2024 | Buy Now | 32.53% | UBS | Ashwani Verma | $174 → $193 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 20.17% | Evercore ISI Group | Cory Kasimov | → $175 | Initiates | → Outperform | Get Alert |
| 05/03/2024 | Buy Now | 3% | Citigroup | David Hoang | $140 → $150 | Maintains | Neutral | Get Alert |
| 05/02/2024 | Buy Now | 12.61% | Canaccord Genuity | Sumant Kulkarni | $154 → $164 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | 16.73% | Guggenheim | Yatin Suneja | $164 → $170 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | 16.05% | Barclays | Carter Gould | $150 → $169 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | -5.24% | BMO Capital | Evan Seigerman | $129 → $138 | Maintains | Market Perform | Get Alert |
| 05/02/2024 | Buy Now | 48.32% | Oppenheimer | Jay Olson | $200 → $216 | Maintains | Outperform | Get Alert |
| 05/02/2024 | Buy Now | 9.87% | HC Wainwright & Co. | Andrew Fein | $150 → $160 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | — | Needham | Ami Fadia | — | Reiterates | → Hold | Get Alert |
| 05/01/2024 | Buy Now | — | Needham | Ami Fadia | — | Reiterates | → Hold | Get Alert |
| 04/24/2024 | Buy Now | 3% | HC Wainwright & Co. | Andrew Fein | → $150 | Reiterates | Buy → Buy | Get Alert |
| 04/24/2024 | Buy Now | 16.73% | Wells Fargo | Mohit Bansal | $140 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/24/2024 | Buy Now | 37.33% | Oppenheimer | Jay Olson | $200 → $200 | Maintains | Outperform | Get Alert |
| 04/23/2024 | Buy Now | — | Needham | Ami Fadia | — | Reiterates | → Hold | Get Alert |
| 04/17/2024 | Buy Now | 0.94% | Wedbush | Laura Chico | → $147 | Reiterates | Outperform → Outperform | Get Alert |
| 04/10/2024 | Buy Now | 6.43% | Cantor Fitzgerald | Charles Duncan | → $155 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 8.49% | JP Morgan | Anupam Rama | $148 → $158 | Maintains | Overweight | Get Alert |
| 03/13/2024 | Buy Now | 37.33% | Oppenheimer | Jay Olson | $170 → $200 | Maintains | Outperform | Get Alert |
| 02/23/2024 | Buy Now | 1.63% | JP Morgan | Anupam Rama | $154 → $148 | Maintains | Overweight | Get Alert |
| 02/08/2024 | Buy Now | -3.87% | Citigroup | David Hoang | $141 → $140 | Maintains | Neutral | Get Alert |
| 02/08/2024 | Buy Now | -3.87% | Mizuho | Uy Ear | $116 → $140 | Maintains | Neutral | Get Alert |
| 02/08/2024 | Buy Now | -3.87% | Wells Fargo | Mohit Bansal | $127 → $140 | Maintains | Equal-Weight | Get Alert |
| 01/25/2024 | Buy Now | 5.06% | Goldman Sachs | Chris Shibutani | $134 → $153 | Maintains | Buy | Get Alert |
| 01/23/2024 | Buy Now | 3% | Barclays | Carter Gould | $145 → $150 | Maintains | Overweight | Get Alert |
| 12/18/2023 | Buy Now | -1.12% | Stifel | Paul Matteis | $141 → $144 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | -12.79% | Wells Fargo | Mohit Bansal | $110 → $127 | Maintains | Equal-Weight | Get Alert |
| 12/13/2023 | Buy Now | -12.79% | Citigroup | David Hoang | → $127 | Initiates | → Neutral | Get Alert |
| 12/12/2023 | Buy Now | -6.61% | Deutsche Bank | Neena Bitritto-Garg | → $136 | Initiates | → Buy | Get Alert |
| 12/07/2023 | Buy Now | 3% | Canaccord Genuity | Sumant Kulkarni | → $150 | Reiterates | Buy → Buy | Get Alert |
| 11/10/2023 | Buy Now | -31.33% | BMO Capital | Evan Seigerman | $111 → $100 | Maintains | Market Perform | Get Alert |
| 11/10/2023 | Buy Now | -16.91% | RBC Capital | Brian Abrahams | $128 → $121 | Maintains | Sector Perform | Get Alert |
| 11/10/2023 | Buy Now | -21.72% | Mizuho | Uy Ear | $116 → $114 | Maintains | Neutral | Get Alert |
| 11/03/2023 | Buy Now | -20.35% | Mizuho | Uy Ear | — | Maintains | Neutral | Get Alert |
| 11/01/2023 | Buy Now | -12.11% | RBC Capital | Brian Abrahams | $123 → $128 | Maintains | Sector Perform | Get Alert |
| 11/01/2023 | Buy Now | -31.33% | Piper Sandler | David Amsellem | $95 → $100 | Maintains | Neutral | Get Alert |
| 11/01/2023 | Buy Now | -0.43% | Raymond James | Danielle Brill | $135 → $145 | Maintains | Outperform | Get Alert |
| 10/24/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan | — | Assumes | → Overweight | Get Alert |
| 10/06/2023 | Buy Now | 13.3% | Oppenheimer | Jay Olson | $160 → $165 | Maintains | Outperform | Get Alert |
| 10/06/2023 | Buy Now | 3% | HC Wainwright & Co. | Andrew Fein | $146 → $150 | Maintains | Buy | Get Alert |
| 09/13/2023 | Buy Now | -1.12% | Canaccord Genuity | Sumant Kulkarni | $132 → $144 | Maintains | Buy | Get Alert |
| 09/13/2023 | Buy Now | -22.41% | Mizuho | Uy Ear | → $113 | Reiterates | Neutral → Neutral | Get Alert |
| 09/13/2023 | Buy Now | -5.93% | Wedbush | Laura Chico | $120 → $137 | Maintains | Outperform | Get Alert |
| 09/13/2023 | Buy Now | -7.99% | JP Morgan | Anupam Rama | $133 → $134 | Maintains | Overweight | Get Alert |
| 09/13/2023 | Buy Now | -6.61% | Cantor Fitzgerald | Charles Duncan | → $136 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | Buy Now | -23.78% | BMO Capital | Evan Seigerman | $100 → $111 | Maintains | Market Perform | Get Alert |
| 09/13/2023 | Buy Now | 0.25% | HC Wainwright & Co. | Andrew Fein | → $146 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | Buy Now | -6.61% | Cantor Fitzgerald | Charles Duncan | → $136 | Reiterates | Overweight → Overweight | Get Alert |
| 08/21/2023 | Buy Now | 5.75% | Oppenheimer | Jay Olson | $150 → $154 | Maintains | Outperform | Get Alert |
| 08/21/2023 | Buy Now | 0.25% | HC Wainwright & Co. | Andrew Fein | $140 → $146 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | -9.36% | Canaccord Genuity | Sumant Kulkarni | $130 → $132 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | -3.87% | HC Wainwright & Co. | Andrew Fein | → $140 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | -24.47% | RBC Capital | Brian Abrahams | $108 → $110 | Maintains | Sector Perform | Get Alert |
| 08/02/2023 | Buy Now | -10.73% | Morgan Stanley | Jeffrey Hung | $130 → $130 | Reiterates | Overweight → Overweight | Get Alert |
| 08/02/2023 | Buy Now | -31.33% | BMO Capital | Evan Seigerman | $96 → $100 | Maintains | Market Perform | Get Alert |
| 08/02/2023 | Buy Now | -23.09% | Mizuho | Uy Ear | $111 → $112 | Maintains | Neutral | Get Alert |
| 08/02/2023 | Buy Now | 3% | Oppenheimer | Jay Olson | → $150 | Reiterates | Outperform → Outperform | Get Alert |
| 08/02/2023 | Buy Now | 1.63% | Baird | Brian Skorney | $140 → $148 | Maintains | Outperform | Get Alert |
| 07/13/2023 | Buy Now | -21.03% | UBS | Ashwani Verma | $121 → $115 | Maintains | Buy | Get Alert |
| 07/11/2023 | Buy Now | -10.73% | Morgan Stanley | Jeffrey Hung | $130 → $130 | Reiterates | Overweight → Overweight | Get Alert |
| 07/06/2023 | Buy Now | -34.08% | BMO Capital | Evan Seigerman | $91 → $96 | Upgrade | Underperform → Market Perform | Get Alert |
| 06/30/2023 | Buy Now | -25.84% | RBC Capital | Brian Abrahams | → $108 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 06/06/2023 | Buy Now | -14.17% | Stifel | Paul Matteis | $145 → $125 | Maintains | Buy | Get Alert |
| 06/05/2023 | Buy Now | -25.84% | RBC Capital | Brian Abrahams | $106 → $108 | Reiterates | → Sector Perform | Get Alert |
| 05/04/2023 | Buy Now | -27.21% | RBC Capital | Brian Abrahams | $110 → $106 | Maintains | Sector Perform | Get Alert |
| 05/04/2023 | Buy Now | -10.73% | Canaccord Genuity | Sumant Kulkarni | $132 → $130 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | -0.43% | Guggenheim | Yatin Suneja | → $145 | Upgrade | Neutral → Buy | Get Alert |
| 05/04/2023 | Buy Now | -24.47% | Wells Fargo | Mohit Bansal | $115 → $110 | Maintains | Equal-Weight | Get Alert |
| 05/04/2023 | Buy Now | -23.78% | Mizuho | Uy Ear | $116 → $111 | Maintains | Neutral | Get Alert |
| 05/04/2023 | Buy Now | -16.23% | Citigroup | Neena Bitritto-Garg | $127 → $122 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | -14.17% | Barclays | Carter Gould | $131 → $125 | Maintains | Overweight | Get Alert |
| 05/02/2023 | Buy Now | 3% | Oppenheimer | Jay Olson | → $150 | Reiterates | → Outperform | Get Alert |
| 04/24/2023 | Buy Now | -24.47% | RBC Capital | Brian Abrahams | $108 → $110 | Maintains | Sector Perform | Get Alert |
| 04/19/2023 | Buy Now | -12.79% | Citigroup | Neena Bitritto-Garg | $131 → $127 | Maintains | Buy | Get Alert |
| 04/17/2023 | Buy Now | -12.11% | Wedbush | Laura Chico | $131 → $128 | Maintains | Outperform | Get Alert |
| 04/14/2023 | Buy Now | -20.35% | Mizuho | Uy Ear | → $116 | Reiterates | → Neutral | Get Alert |
| 04/04/2023 | Buy Now | -14.17% | UBS | Ashwani Verma | $137 → $125 | Maintains | Buy | Get Alert |
| 03/30/2023 | Buy Now | -9.36% | Canaccord Genuity | Sumant Kulkarni | $124 → $132 | Upgrade | Hold → Buy | Get Alert |
| 03/03/2023 | Buy Now | -10.73% | Evercore ISI Group | Joshua Schimmer | → $130 | Upgrade | In-Line → Outperform | Get Alert |
| 02/07/2023 | Buy Now | -24.47% | RBC Capital | Brian Abrahams | $122 → $110 | Maintains | Sector Perform | Get Alert |
| 02/07/2023 | Buy Now | -21.03% | Wells Fargo | Mohit Bansal | $120 → $115 | Maintains | Equal-Weight | Get Alert |
| 02/07/2023 | Buy Now | -20.35% | Mizuho | Uy Ear | → $116 | Maintains | Neutral | Get Alert |
| 02/07/2023 | Buy Now | -10.05% | Wedbush | Laura Chico | $125 → $131 | Maintains | Outperform | Get Alert |
| 02/07/2023 | Buy Now | -12.79% | Cantor Fitzgerald | Charles Duncan | $132 → $127 | Reiterates | → Overweight | Get Alert |
| 02/07/2023 | Buy Now | -10.05% | Citigroup | Neena Bitritto-Garg | $133 → $131 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | -10.05% | Barclays | Carter Gould | $136 → $131 | Maintains | Overweight | Get Alert |
| 02/07/2023 | Buy Now | -34.77% | Piper Sandler | David Amsellem | $103 → $95 | Maintains | Neutral | Get Alert |
| 02/07/2023 | Buy Now | -3.87% | HC Wainwright & Co. | Andrew Fein | → $140 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | -10.73% | Morgan Stanley | Jeffrey Hung | $120 → $130 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/14/2022 | Buy Now | -10.73% | Evercore ISI Group | Josh Schimmer | $140 → $130 | Downgrade | Outperform → In-Line | Get Alert |
| 11/03/2022 | Buy Now | -1.81% | JP Morgan | Anupam Rama | $138 → $143 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | -7.3% | Raymond James | Danielle Brill | $125 → $135 | Maintains | Outperform | Get Alert |
| 11/02/2022 | Buy Now | -17.6% | Wells Fargo | Mohit Bansal | $110 → $120 | Maintains | Equal-Weight | Get Alert |
| 11/02/2022 | Buy Now | -20.35% | Mizuho | Uy Ear | $105 → $116 | Maintains | Neutral | Get Alert |
| 11/02/2022 | Buy Now | -9.36% | Cantor Fitzgerald | Charles Duncan | $127 → $132 | Maintains | Overweight | Get Alert |
| 11/02/2022 | Buy Now | -19.66% | RBC Capital | Brian Abrahams | $101 → $117 | Maintains | Sector Perform | Get Alert |
FAQ
What is the target price for Neurocrine Biosciences (NBIX) stock?
The latest price target for Neurocrine Biosciences (NASDAQ:NBIX) was reported by Morgan Stanley on July 12, 2024. The analyst firm set a price target for $170.00 expecting NBIX to rise to within 12 months (a possible 16.73% upside). 62 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Neurocrine Biosciences (NBIX)?
The latest analyst rating for Neurocrine Biosciences (NASDAQ:NBIX) was provided by Morgan Stanley, and Neurocrine Biosciences maintained their overweight rating.
When was the last upgrade for Neurocrine Biosciences (NBIX)?
The last upgrade for Neurocrine Biosciences Inc happened on April 24, 2024 when Wells Fargo raised their price target to $170. Wells Fargo previously had an equal-weight for Neurocrine Biosciences Inc.
When was the last downgrade for Neurocrine Biosciences (NBIX)?
The last downgrade for Neurocrine Biosciences Inc happened on November 14, 2022 when Evercore ISI Group changed their price target from $140 to $130 for Neurocrine Biosciences Inc.
When is the next analyst rating going to be posted or updated for Neurocrine Biosciences (NBIX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on July 12, 2024 so you should expect the next rating to be made available sometime around July 12, 2025.
Is the Analyst Rating Neurocrine Biosciences (NBIX) correct?
While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a maintained with a price target of $160.00 to $170.00. The current price Neurocrine Biosciences (NBIX) is trading at is $145.63, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.